Free tool
FAERS Monitor: Tofidence
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761354 or its brand name (Tofidence, Tocilizumab-Bavi). Reports on generic versions are filed under their own applications.
Reports
31,081
Serious
29,571
95% of reports
Hospitalization
13,341
Death reported
6,642
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use9,475
- drug ineffective7,201
- rheumatoid arthritis5,112
- pain4,584
- fatigue3,997
- rash3,915
- contraindicated product administered3,630
- drug intolerance3,389
- arthropathy3,343
- product use issue3,272
- alopecia3,265
- arthralgia3,261
- treatment failure3,252
- systemic lupus erythematosus3,251
- hypersensitivity3,199
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 11 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 10 |
| 2010 | 520 |
| 2011 | 424 |
| 2012 | 512 |
| 2013 | 663 |
| 2014 | 449 |
| 2015 | 474 |
| 2016 | 617 |
| 2017 | 751 |
| 2018 | 1,218 |
| 2019 | 1,328 |
| 2020 | 3,306 |
| 2021 | 4,517 |
| 2022 | 4,692 |
| 2023 | 3,479 |
| 2024 | 3,519 |
| 2025 | 2,789 |
| 2026 | 1,796 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,078 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contraindicated product administeredSignal | 3,630 | 92.0 | 89.1 | 288,053 |
| systemic lupus erythematosusSignal | 3,251 | 68.1 | 65.8 | 195,617 |
| arthropathySignal | 3,343 | 43.2 | 41.8 | 129,938 |
| rheumatoid arthritisSignal | 5,112 | 31.9 | 31.0 | 146,688 |
| treatment failureSignal | 3,252 | 27.6 | 26.7 | 80,414 |
| drug intoleranceSignal | 3,389 | 24.6 | 23.8 | 74,248 |
| product use issueSignal | 3,272 | 12.0 | 11.6 | 32,611 |
| hypersensitivitySignal | 3,199 | 11.8 | 11.5 | 31,497 |
| alopeciaSignal | 3,265 | 11.4 | 11.1 | 30,817 |
| off label useSignal | 9,475 | 7.4 | 7.3 | 54,045 |
| rashSignal | 3,915 | 6.1 | 5.9 | 16,980 |
| arthralgiaSignal | 3,261 | 5.3 | 5.2 | 11,643 |
| painSignal | 4,584 | 5.1 | 4.9 | 15,355 |
| drug ineffectiveSignal | 7,201 | 3.7 | 3.6 | 15,138 |
| fatigueSignal | 3,997 | 3.5 | 3.4 | 7,322 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.